Bi-Specific T Cell Engagers (BiTE) is a current cancer immunotherapy platform. Despite its clinical success, BiTEs have several limitations which make them less effective. In this project, a novel immunotherapy platform was introduced: ABiTES (Aptamer based BiTEs). ABiTEs help immune cells recognize cancer cells and are safer, cheaper and more effective than BiTEs. ABiTEs could provide patients a better and affordable alternative to current immunotherapies.
Bhavya Mohan
Bi-Specific T Cell Engagers (BiTE) is a current cancer immunotherapy platform. Despite its clinical success, BiTEs have several limitations which make them less effective. In this project, a novel immunotherapy platform was introduced: ABiTES (Aptamer based BiTEs). ABiTEs help immune cells recognize cancer cells and are safer, cheaper and more effective than BiTEs. ABiTEs could provide patients a better and affordable alternative to current immunotherapies.